-
Something wrong with this record ?
Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity
ÍA. Fernandes, D. Braga Resende, TC. Ramalho, K. Kuca, EFF. da Cunha
Language English Country Switzerland
Document type Journal Article
Grant support
CAPES
CNPq
Excellence project
UHK
CEP Register
NLK
Directory of Open Access Journals
from 1997
Free Medical Journals
from 1997
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 1997-01-01
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 2009-03-01
Health & Medicine (ProQuest)
from 1997-01-01
- MeSH
- Enzyme Activation drug effects MeSH
- Algorithms MeSH
- Aurora Kinase B antagonists & inhibitors chemistry MeSH
- Inhibitory Concentration 50 MeSH
- Protein Kinase Inhibitors chemistry pharmacology MeSH
- Humans MeSH
- Molecular Conformation MeSH
- Models, Molecular MeSH
- Molecular Structure MeSH
- Models, Theoretical * MeSH
- fms-Like Tyrosine Kinase 3 antagonists & inhibitors chemistry MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
FLT3 and dual Aurora B/FLT3 inhibitors have shown relevance in the search for promising new anticancer compounds, mainly for acute myeloid leukemia (AML). This study was designed to investigate the interactions between human FLT3 in the kinase domain with several indolin-2-one derivatives, structurally similar to Sunitinib. Molegro Virtual Docker (MVD) software was utilized in docking analyses. The predicted model of the training group, considering nineteen amino acid residues, performed in Chemoface, achieved an R2 of 0.82, suggesting that the binding conformations of the ligands with FLT3 are reasonable, and the data can be used to predict the interaction energy of other FLT3 inhibitors with similar molecular patterns. The MolDock Score for energy for compound 1 showed more stable interaction energy (-233.25 kcal mol-1) than the other inhibitors studied, while Sunitinib presented as one of the least stable (-160.94 kcal mol-1). Compounds IAF70, IAF72, IAF75, IAF80, IAF84, and IAF88 can be highlighted as promising derivatives for synthesis and biological evaluation against FLT3. Furthermore, IAF79 can be considered to be a promising dual Aurora B/FLT3 inhibitor, and its molecular pattern can be exploited synthetically to search for new indolin-2-one derivatives that may become drugs used in the treatment of cancers, including AML.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012712
- 003
- CZ-PrNML
- 005
- 20210507103633.0
- 007
- ta
- 008
- 210420s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules25071726 $2 doi
- 035 __
- $a (PubMed)32283751
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Fernandes, Ítalo Antônio $u Department of Chemistry, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil
- 245 10
- $a Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity / $c ÍA. Fernandes, D. Braga Resende, TC. Ramalho, K. Kuca, EFF. da Cunha
- 520 9_
- $a FLT3 and dual Aurora B/FLT3 inhibitors have shown relevance in the search for promising new anticancer compounds, mainly for acute myeloid leukemia (AML). This study was designed to investigate the interactions between human FLT3 in the kinase domain with several indolin-2-one derivatives, structurally similar to Sunitinib. Molegro Virtual Docker (MVD) software was utilized in docking analyses. The predicted model of the training group, considering nineteen amino acid residues, performed in Chemoface, achieved an R2 of 0.82, suggesting that the binding conformations of the ligands with FLT3 are reasonable, and the data can be used to predict the interaction energy of other FLT3 inhibitors with similar molecular patterns. The MolDock Score for energy for compound 1 showed more stable interaction energy (-233.25 kcal mol-1) than the other inhibitors studied, while Sunitinib presented as one of the least stable (-160.94 kcal mol-1). Compounds IAF70, IAF72, IAF75, IAF80, IAF84, and IAF88 can be highlighted as promising derivatives for synthesis and biological evaluation against FLT3. Furthermore, IAF79 can be considered to be a promising dual Aurora B/FLT3 inhibitor, and its molecular pattern can be exploited synthetically to search for new indolin-2-one derivatives that may become drugs used in the treatment of cancers, including AML.
- 650 _2
- $a algoritmy $7 D000465
- 650 _2
- $a aurora kinasa B $x antagonisté a inhibitory $x chemie $7 D064107
- 650 _2
- $a aktivace enzymů $x účinky léků $7 D004789
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a molekulární modely $7 D008958
- 650 12
- $a teoretické modely $7 D008962
- 650 _2
- $a molekulární konformace $7 D008968
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a inhibitory proteinkinas $x chemie $x farmakologie $7 D047428
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a tyrosinkinasa 3 podobná fms $x antagonisté a inhibitory $x chemie $7 D051941
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Braga Resende, Déborah $u Department of Veterinary Medicine, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil
- 700 1_
- $a Ramalho, Teodorico Castro $u Department of Chemistry, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil $u Faculty of Science, Department of Chemistry, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
- 700 1_
- $a Kuca, Kamil $u Faculty of Science, Department of Chemistry, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
- 700 1_
- $a da Cunha, Elaine Fontes Ferreira $u Department of Chemistry, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 25, č. 7 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32283751 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507103632 $b ABA008
- 999 __
- $a ok $b bmc $g 1650971 $s 1133091
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 25 $c 7 $e 20200409 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a CAPES $p CNPq
- GRA __
- $a Excellence project $p UHK
- LZP __
- $a Pubmed-20210420